Effects of Botulinum Toxin Type A Injection in Patients with Bruxism and Masseter Muscle Hypertrophy

Yıl 2023, Cilt: 33 Sayı: 3, 138 - 141, 31.07.2023

Songül Cömert Kılıç

https://doi.org/10.5152/CRDS.2023.223029

Öz

ABSTRACT
Objective: The aim of this study was to evaluate the efficacy of botulinum toxin type A injection on the severity and incidents of bruxism and joint noise and for pain in patients during the manage- ment of bruxism and masseter muscle hypertrophy.
Methods: Sixteen adults who had bruxism and bilateral masseter muscle hypertrophy were included in this study. One-session 30 U botulinum toxin type A injection was performed. Maximum interincisal mouth opening, visual analog scale evaluations, and severity and incident of bruxism were recorded at 3 times: baseline and 1 month and 8 months after the injection. Patient satisfaction was assessed only at 8 months after the injection.
Results: Significant decreases were observed in pain complaints, restriction in mouth opening, and severity of bruxism at 1 month and 8 months. Bite force decreased significantly at 1 month, but it returned to baseline levels at 8 months. Self-perceived pathologic sound decreased significantly at 8 months. No significant change was observed in painless maximum interincisal mouth opening and mastication efficiency at 1 month and 8 months. Patient satisfaction was good at 8 months.
Conclusion: Botulinum toxin type A injection lessened severity and incidents of bruxism and reduced joint noise and pain in patients with bruxism and masseter muscle hypertrophy, and botulinum toxin type A injection produced greater patient satisfaction.
Keywords: Botulinum toxin Type A, bruxism, masseter muscle hypertrophy
ÖZ
Amaç: Bu çalışmanın amacı; bruksizm ve masseter kas hipertrofisi tedavisi gören hastalarda Botulinum Toksin Tip A enjeksiyonunun bruksizm şiddeti ve sıklığı ile eklem ağrısı ve sesi üzerin- deki etkinliğinin incelenmesidir.
Yöntemler: Bu çalışma bruksizm ve çift taraflı masseter kas hipertrofisi olan 16 erişkin hastayı içermektedir. Hastalara 30 U Botulinum Toksin Tip A enjeksiyonu yapılmıştır. Maksimum ağız açıklığı miktarı, görsel analog skala incelemeleri ile bruksizm şiddeti ve sıklığı 3 farklı zamanda kayıt edilmiştir: Tedavi başında, enjeksiyondan 1 ay sonra ve enjeksiyondan 8 ay sonra. Hasta memnuniyeti ise sadece enjeksiyondan 8 ay sonra değerlendirilmiştir.
Bulgular: Ağrı şikâyetleri, ağız açmadaki kısıtlılık ve bruksizmin şiddetinde tedavinin 1. ve 8. aylarında önemli azalmalar gözlemlenmiştir. Isırma kuvveti tedavinin 1. ayında önemli şekilde azalmış fakat tedavinin 8 ayında tedavi başlangıcındaki seviyelere geri dönmüştür. Bireysel olarak algılanan patolojik eklem sesi tedavinin 8. ayında önemli şekilde azalmıştır. Ağrısız maksimum ağız açıklığı ve çiğneme etkinliğinde tedavinin 1. ve 8. aylarında önemli değişimler gözlemlenmemiştir. Tedavinin 8. ayındaki hasta memnuniyet seviyesinin iyi olduğu görülmüştür.
Sonuç: Bruksizm ve masseter kas hipertrofisi olan hastalarda; Botulinum Toksin Tip A enjeksiyonu bruksizm şiddeti ve sıklığı ile eklem ağrısı ve sesini azalmıştır ve Botulinum Toksin Tip A enjeksi- yonu yüksek oranda hasta memnuniyeti oluşturmuştur.
Anahtar Kelimeler: Botulinum toksin tip A, bruksizm, masseter kas hipertrofisi

Anahtar Kelimeler

Botulinum toxin Type A, bruxism, masseter muscle hypertrophy

Kaynakça

• 1. Reddy SV, Kumar MP, Sravanthi D, Mohsin AH, Anuhya V. Bruxism: a literature review. J Int Oral Health. 2014;6(6):105-109.
• 2. Rauso R, Lo Giudice G, Tartaro G, Zerbinati N, Nicoletti GF, Fragola R. Botulinum toxin type A injections for masticatory muscles hypertro- phy: a systematic review. J Craniomaxillofac Surg. 2022;50(1):7-18. [CrossRef]
• 3. Coffield JA, CR, Simpson LL. the site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994.
• 4. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990;53(6):530. [CrossRef]
• 5. To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultra- sonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200. [CrossRef]
• 6. Almukhtar RM, Fabi SG. The masseter muscle and its role in facial contouring, aging, and quality of life: a literature review. Plast Recon- str Surg. 2019;143(1):39e-48e. [CrossRef]
• 7. Quezada-Gaon N, Wortsman X, Peñaloza O, Carrasco JE. Compari- son of clinical marking and ultrasound-guided injection of Botuli- num type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol. 2016;15(3):238-244. [CrossRef]
• 8. Lee SH, Wee SH, Kim HJ, et al. Abobotulinum toxin A and Onabot- ulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. J Dermatolog Treat. 2013;24(2):133-136. [CrossRef]
• 9. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125(6):1693-1705. [CrossRef]
• 10. Lee DH, Jin SP, Cho S, et al. RimabotulinumtoxinB versus onabotu- linumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study. Dermatology. 2013;226(3):227-232. [CrossRef]
• 11. Ahn KY, Kim ST. The change of maximum bite force after botulinum toxin type A injection for treating masseteric hypertrophy. Plast Reconstr Surg. 2007;120(6):1662-1666. [CrossRef] 12. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008;26(2):126- 135. [CrossRef]
• 13. Cömert Kiliç S, Güngörmüş M. Is dextrose prolotherapy superior to placebo for the treatment of temporomandibular joint hypermobil- ity? A randomized clinical trial. Int J Oral Maxillofac Surg. 2016;45(7):813-819. [CrossRef]
• 14. Lee HJ, Kim SJ, Lee KJ, Yu HS, Baik HS. Repeated injections of botu- linum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J Orthod. 2017;47(4):222-228. [CrossRef]
• 15. Song JH, Cho ES, Kim ST, Ahn HJ. Change of distribution and timing of bite force after botulinum toxin type A injection evaluated by a computerized occlusion analysis system. Yonsei Med J. 2014;55(4):1123-1129. [CrossRef]
• 16. Redaelli A. Botulinum toxin A in bruxers. One year experience. Saudi Med J. 2011;32(2):156-158.
• 17. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J. 2012;62(1):1-5. [CrossRef]
• 18. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324(17):1186-1194. [CrossRef]
• 19. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharma- col Exp Ther. 1980;212(1):16-21